# Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

> **NCT04164901** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 331 (actual)

## Conditions studied

- Grade 2 Glioma
- Residual Glioma
- Recurrent Glioma

## Interventions

- **DRUG:** Vorasidenib
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT04164901
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-05
- **Primary completion:** 2022-09-06
- **Final completion:** 2028-05
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04164901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04164901, "Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04164901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*